Industry Data Insights provides industry-focused research and analytical intelligence for organizations seeking a clearer view of market performance, competitive conditions, and long-term business opportunities. Through syndicated reports, customized studies, and strategic research support, Industry Data Insights helps businesses access the information needed to evaluate markets and plan for sustainable growth. Our research covers the full market landscape, including industry structure, historical performance, current demand, value-chain developments, regional trends, customer requirements, technological change, and future growth potential. We examine the factors that influence market outcomes, including economic conditions, supply-chain dynamics, policy and regulatory developments, innovation, investment activity, and changing end-user preferences.
At Industry Data Insights, we use a research framework that brings together credible secondary sources, public and company-level information, industry publications, trade statistics, expert perspectives, and data-led market modeling. Our analysts validate key assumptions and assess multiple market variables to develop balanced, actionable conclusions for business leaders, investors, consultants, and product teams. Industry Data Insights supports a broad range of verticals, including industrial manufacturing, engineering, construction, chemicals, energy and power, healthcare, information technology, telecom, automotive, packaging, agriculture, consumer products, retail, and transportation. Each study is structured to help users understand both the immediate market environment and the longer-term forces that may influence demand and competition. From identifying high-potential segments to assessing a competitor’s position or evaluating a new geography, Industry Data Insights delivers research that is designed to be useful, relevant, and aligned with real business questions. Our goal is to turn industry data into strategic direction.
Sep 7 2026
274
.jpg){kind=small}
Research Analyst
Access in-depth insights on industries, companies, trends, and global markets. Our expertly curated reports provide the most relevant data and analysis in a condensed, easy-to-read format.
See the similar reports
| Metric | Value |
|---|---|
| Base Year (2025) Valuation | $34.8 Billion |
| Forecast Year (2033) Valuation | $66.1 Billion |
| CAGR (2025–2033) | 8.3% |
| Forecast Period | 2025–2033 |
| Largest Regional Market | North America |
| Dominant Segment | Tissue Biopsy |
The Cancer Biopsy Market is valued at $34.8 Billion in 2025 and is projected to reach $66.1 Billion by 2033. The 8.3% CAGR is an average across two distinct trajectories: the Tissue Biopsy Market, which supplies most revenue through definitive histology, and the faster-growing Liquid Biopsy Market, which adds blood-based tumor profiling for early detection and minimal residual disease monitoring. North America contributes 42% of global revenue in the base year, while Europe adds 25%. Asia-Pacific is the fastest-growing region, with a projected CAGR near 10.5%, driven by central laboratory expansion and public cancer screening programs.
Customers are shifting from one-off device procurement to lifecycle agreements that include extraction kits, sequencing consumables, digital pathology storage, and physician interpretation services. This integration links tissue and liquid workflows with the broader Oncology Diagnostics Market and elevates the importance of the Cancer Biomarker Testing Market. By the terminal year, precision oncology reimbursement will determine how much revenue flows to tissue versus liquid platforms.
Key signals for planning include a rising rate of repeat biopsy due to insufficient tissue, expanding payer acceptance of ctDNA-based molecular residual disease tests, and consolidation of biopsy products into managed diagnostic contracts. Vendors that can prove reliable tissue adequacy and liquid concordance will gain share. Investors should monitor ASP erosion in DNA extraction kits and the speed of regulatory approval under IVDR.
Tissue biopsy is the dominant segment and contributed more than half of Cancer Biopsy Market revenue in 2025. Its economic center lies in image-guided Needle Biopsy Market volumes used for lung, breast, liver, and prostate lesions. Within this segment, core needle biopsy (CNB) is preferred over surgical biopsy where anatomic risk is low because it preserves tissue architecture, is cheaper to perform, and supports molecular analysis. CNB and fine needle aspiration (FNA) follow different demand curves, with CNB growing faster as robotic and electromagnetic navigation improves lesion targeting.
From a product standpoint, instruments and imaging guidance devices are the strategic entry points, but kits and consumables produce the recurring revenue. Biopsy needles, introducer sheaths, formalin containers, and molecular fixatives are purchased repeatedly, making the kits and consumables line the most predictable within the Tissue Biopsy Market. Service revenue from central laboratory histology and remote pathology is secondary but increasing as hospitals outsource complicated biomarker interpretation.
The largest applications by procedure volume in tissue biopsy are breast, colorectal, lung, prostate, and skin. Breast Cancer Screening Market growth increases the number of image-detected lesions requiring needle verification; lung cancer screening using low-dose CT adds the same pull for peripheral pulmonary nodules. Rising use of neoadjuvant therapy, however, is lowering surgical biopsy percentage and creating more demand for pre-treatment core sampling.
The Tissue Biopsy Market faces margin pressure from commodity needle suppliers based in Asia and from hospital GPOs that use reference pricing. Differentiation is moving toward preservation media compatible with next-generation sequencing and companion diagnostic assays. This is part of the Precision Medicine Market because pathologists now order tissue-based biomarker panels before selecting initial therapy. The clinical outcome is a higher diagnostic yield per biopsy event, which rewards suppliers that solve the fragmentation problem.
Demand is primarily set by cancer incidence growth, targeted therapy approvals, and laboratory investment in early cancer detection. The global incident cancer population is expanding by roughly 2 million cases per year, and every solid tumor needs at least one high-quality tissue sample at diagnosis. At the same time, regulatory agencies are reviewing companion diagnostics alongside therapeutics. Each combination expands the Cancer Biomarker Testing Market because payers require biomarkers before releasing drug spend. These molecular needs are built into the In Vitro Diagnostics Market because many hospital laboratories run biopsy-derived samples on the same extraction and PCR infrastructure used for other disease areas.
Liquid biopsy also serves patients who cannot undergo invasive sampling or whose image-guided biopsy returned an indeterminate result. This broadens the addressable base of the Liquid Biopsy Market without cannibalizing all tissue procedures, since therapy response monitoring now occurs through repeated ctDNA draws.
The most stubborn restraint is reimbursement complexity. NCCI and local coverage determinations still divide tests by analyte; a single multi-marker liquid biopsy panel can encounter partial denials if all markers are not separately recognized. Laboratory developed tests face new FDA oversight under the LDT rule, increasing compliance cost. On the supply side, biopsy needles and vacuum-assisted devices are exposed to aluminum, polymer resin, and sterile packaging shortages, which create procurement delays. Across the global marketplace, Asia-Pacific private pathology groups face limited access to international reference materials, complicating quality control.
The common thread is that demand per cancer case is rising while the unit price of sequencing is falling. Growth will continue, but profitability will depend on consolidating test volume and achieving scale in bioinformatics interpretation rather than manufacturing.
The competitive emphasis is less on product patent expiry and more on the strength of clinical evidence, reimbursement coverage, and pathway integration with electronic health records.
These milestones indicate that the market is shifting away from purely manual, histology-only sampling and toward integrated molecular diagnostics and automated interventional procedures.
North America is the most mature market and remains highly profitable because reimbursement supports both interventional radiology and genomic testing. The U.S. is the largest single country, with regional reference laboratory competition centered on Guardant Health, Exact Sciences, and Natera. Canada contributes a smaller but stable flow of public-sector procedures through provincial cancer agencies.
Europe accounts for close to one-quarter of global value. Germany and France lead in tissue diagnostics, while the United Kingdom drives ctDNA studies through Genomics England and NHS cancer pathways. EU IVDR compliance has raised evidence-generation costs for small in vitro diagnostic vendors, slowing the speed of product introduction in Southern Europe.
Asia-Pacific is the key growth corridor. China, Japan, and South Korea have large installed NGS bases and aggressive early-screening reimbursement for certain cancers. India and ASEAN countries show demand for low-cost, high-volume tissue biopsy consumables, with services and interpretation still concentrated in urban academic centers.
South America and the Middle East and Africa account for the remaining small share of global value. Brazil and Mexico are the main Latin American purchasers; in the Middle East, GCC countries use international oncology networks and central procurement to access modern liquid biopsy services. The fastest growth is in Asia-Pacific, whereas North America offers the largest single-source revenue pool.
ESG criteria are now part of vendor qualification in many hospital and reference laboratory tenders. Biopsy kits produce substantial plastic and packaging waste, and reprocessing of single-use devices is being revisited where regulators allow reuse after cleaning and sterilization. European health systems also consider the carbon cost of cold-chain transport for liquid biopsy tubes containing stabilizing reagents. Suppliers are responding with smaller packaging units, recycled polymer content, and committed carbon reporting. Procurement directors increasingly compare suppliers on waste-per-procedure metrics and Scope 3 emissions, not only on clinical accuracy. This pressure may raise short-term production costs, but it will become a qualification threshold during the forecast period.
End users split into hospital pathology departments, commercial reference laboratories, academic medical centers, and biopharmaceutical and R&D organizations. Hospitals buy through GPOs and favor just-in-time inventory; their primary criterion is same-day sample stabilization and workflow compatibility with existing pathology systems. Reference laboratories prioritize test sensitivity, cross-platform compatibility, and throughput. Academic centers and pharma companies buy custom biopsy assays and companion diagnostics in smaller volumes, with a buying cycle tied to clinical trial milestones.
Price elasticity differs by segment. Hospitals are less sensitive to device price if a biopsy instrument lowers complication rates; commercial labs are highly sensitive to per-sample reagent cost because scale determines margin. Digital procurement has expanded: laboratory buyers now require online quote comparisons, electronic data sheets, and interoperability with laboratory information systems. The most recent shift is the purchase of biopsy services under outcome-based contracts, especially in breast and lung cancer pathways, where the Breast Cancer Screening Market and diagnostic accuracy drive total episode cost. Procurement will continue to consolidate in the hands of molecular lab directors and value analysis committees rather than individual physicians.
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 8.3% from 2020-2034 |
| Segmentation |
|
Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.
Report Title: Cancer Biopsy Market, by Product (Instruments, Kits & Consumables, Services), by Type (Tissue Biopsies, Liquid Biopsies, Others), by Application (Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Skin Cancers, Blood Cancers, Kidney Cancers, Liver Cancers, Pancreatic Cancers, Ovarian Cancers, Others), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific), Forecast 2026-2034
| Stakeholder Role | Interview Share (%) |
|---|---|
| Pathology & Lab Directors | 32% |
| Procurement & Supply Chain Managers | 24% |
| Clinical Oncology Researchers | 21% |
| Regulatory Affairs Specialists | 14% |
| Hospital Administrators | 9% |
| Company Type | Representation (%) |
|---|---|
| Device / Instrument Manufacturers | 28% |
| Molecular Diagnostics Assay Providers | 27% |
| Liquid Biopsy Platform Developers | 21% |
| Biopsy Services & CROs | 14% |
| Distribution & Consumables Suppliers | 10% |
Average list price for a tissue core needle biopsy procedure remains in the $2,500-$4,000 range in U.S. hospital outpatient settings, while multi-gene liquid biopsy panels range between $3,000 and $6,000. Vendors bundle bioinformatics and clinical interpretation into the per-test fee to reduce reimbursement uncertainty, shifting more spend into kits and consumables.
Hospital procurement teams are setting Scope 3 emissions targets, asking biopsy kit suppliers to reduce single-use plastic packaging and adopt reprocessing-compatible materials. European institutions also screen vendors against EU Single-Use Plastics and medical waste directives, forcing manufacturers to disclose carbon data and provide take-back programs.
Tissue sample failure occurs in roughly 5-15% of procedures, leading to repeat biopsies and higher episode costs. IVDR evidence requirements and shortages of sequencing consumables extend time-to-market, while cold-chain logistics for liquid biopsy collection tubes remains a fragile point in international laboratory networks.
Precision oncology requires a biomarker result before therapy is selected, which pushes payers and providers to expand both tissue and liquid biopsy capacity. With more targeted oncology drug classes reliant on molecular diagnostics, Asia-Pacific reference laboratories will grow at an estimated 10-12% annual rate, lifting the global average.
The Needle Biopsy Market forms the core of the tissue biopsy segment, while liquid biopsy is the fastest-growing test type. Lung, breast, and colorectal cancers represent the largest application clusters. By product, kits and consumables generate the most recurring revenue, followed by instruments and interpretive services.
The Cancer Biopsy Market is valued at $34.8 billion in 2025. At an 8.3% CAGR, it reaches $66.1 billion by 2033. North America retains the largest regional share, while Asia-Pacific supplies the fastest growth.
